

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM845646

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
CyDex Pharmaceuticals, Inc.		10/12/2023	Corporation: DELAWARE
Ligand Pharmaceuticals Incorporated		10/12/2023	Corporation: DELAWARE
Pfenex Inc.		10/12/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Citibank, N.A., as Administrative Agent		
Street Address:	6400 Las Colinas Blvd., Mail Stop CC1-30		
City:	Irving		
State/Country:	TEXAS		
Postal Code:	75039		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 15			
Property Type	Number	Word Mark	
Registration Number:	6768469	LTP TECHNOLOGY	
Registration Number:	6456158	LTP	
Registration Number:	5181171	LIGAND	
Registration Number:	5181169	LIGAND	
Registration Number:	5092212	LIGAND	
Registration Number:	5938256		
Registration Number:	5829234	CAPTISOL 0 200 ML APPROX 50 150 100 1001	
Registration Number:	3760106	CYDEX PHARMACEUTICALS	
Registration Number:	3713386	CD	
Registration Number:	3479381	CYDEX	
Registration Number:	2205608	ADVASEP	
Registration Number:	2086224	CAPTISOL	
Registration Number:	6153490	BONSITY	
Serial Number:	97056902	BEPRO TECHNOLOGY	
Serial Number:	90588506	BEPRO	
CORRESPONDENCE DATA			

OP \$390.00 6768469

Fax Number: 7043738822

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7043734640

Email: bsmith@mcguirewoods.com

Correspondent Name: Betty G. Smith, Senior Paralegal

Address Line 1: McGuireWoods LLP, 201 N. Tryon St.

Address Line 2: Suite 3000

Address Line 4: Charlotte, NORTH CAROLINA 28202

ATTORNEY DOCKET NUMBER:	5040387-0147
--------------------------------	--------------

NAME OF SUBMITTER:	Betty G. Smith
---------------------------	----------------

SIGNATURE:	/Betty G. Smith/
-------------------	------------------

DATE SIGNED:	10/12/2023
---------------------	------------

Total Attachments: 7

source=Notice of Grant of Security Interest in Trademarks - Ligand (2023)#page1.tif

source=Notice of Grant of Security Interest in Trademarks - Ligand (2023)#page2.tif

source=Notice of Grant of Security Interest in Trademarks - Ligand (2023)#page3.tif

source=Notice of Grant of Security Interest in Trademarks - Ligand (2023)#page4.tif

source=Notice of Grant of Security Interest in Trademarks - Ligand (2023)#page5.tif

source=Notice of Grant of Security Interest in Trademarks - Ligand (2023)#page6.tif

source=Notice of Grant of Security Interest in Trademarks - Ligand (2023)#page7.tif

**NOTICE
OF
GRANT OF SECURITY INTEREST
IN
TRADEMARKS**

United States Patent and Trademark Office


Ladies and Gentlemen:

Please be advised that pursuant to the Security and Pledge Agreement dated as of October 12, 2023 (as amended, modified, extended, restated, renewed, replaced, or supplemented from time to time, the "Agreement") and among the Grantors party thereto (each an "Grantor" and collectively, the "Grantors") and Citibank, N.A., as administrative agent (the "Administrative Agent") for the Secured Parties referenced therein, the undersigned Grantors have granted a continuing security interest in, and a right to set off against, the trademarks and trademark applications shown on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties.

The undersigned Grantors and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the foregoing trademarks and trademark applications (a) may only be terminated in accordance with the terms of the Agreement and (b) is not to be construed as an assignment of any trademark or trademark application.

[SIGNATURE PAGES TO FOLLOW]


CYDEX PHARMACEUTICALS, INC.

By: 

Name: Octavio Espinoza

Title: Chief Financial Officer

LIGAND PHARMACEUTICALS INCORPORATED

By: 

Name: Octavio Espinoza

Title: Chief Financial Officer

[SIGNATURE PAGE TO NOTICE OF GRANT OF SECURITY INTEREST IN TRADEMARKS -
LIGAND PHARMACEUTICALS LIMITED]

TRADEMARK
REEL: 008226 FRAME: 0249

PFENEX INC.


By: 
Name: Octavio Espinoza
Title: Chief Financial Officer

[SIGNATURE PAGE TO NOTICE OF GRANT OF SECURITY INTEREST IN TRADEMARKS --
LIGAND PHARMACEUTICALS LIMITED]

TRADEMARK
REEL: 008226 FRAME: 0250







Acknowledged and Accepted:

CITIBANK, N.A., as Administrative Agent

By: 
Name: JAMES E. TAYLOR, JR.
Title: Vice President

SCHEDULE 1

TRADEMARKS

Mark	(Reg) / Serial No.	Owner	Goods / Services
	97056902 (ITU)	Ligand Pharmaceuticals Incorporated (DE)	42: Pharmaceutical research and development of a process to deliver pharmaceutical preparations
BEPRO	90588506 (ITU)	Ligand Pharmaceuticals Incorporated (DE)	42: Pharmaceutical research and development of a process to deliver pharmaceutical preparations
	(6768469) 88363841	Ligand Pharmaceuticals Incorporated (DE)	42: Pharmaceutical research and development of a process to deliver organ specific pharmaceutical preparations
LTP	(6456158) 88221060	Ligand Pharmaceuticals Incorporated (DE)	42: Pharmaceutical research and development of a process to deliver organ specific pharmaceutical preparations
	(5181171) 87159958	Ligand Pharmaceuticals, Inc. (DE)	45: licensing of pharmaceutical products
LIGAND	(5181169) 87159922	Ligand Pharmaceuticals, Inc. (DE)	45: licensing of pharmaceutical products
LIGAND	(5092212) 86685781	Ligand Pharmaceuticals, Inc. (DE)	42: pharmaceutical research and development
	(5938256) 86844396	Cydex Pharmaceuticals, Inc. (DE)	1: Chemical agents for use in pharmaceutical products, namely, solubilizing agents; solubilizing chemical agents for use in the manufacture of pharmaceutical preparations; solubilization chemicals for diagnostic research; chemical additives for use as binding agents in pharmaceuticals; chemical agents used for improving stability, bioavailability and dosing of pharmaceutical ingredients
	(5829234) 86844402	Cydex Pharmaceuticals, Inc. (DE)	1: Chemical agents for use in pharmaceutical products, namely, solubilizing agents; solubilizing chemical agents for use in the manufacture of pharmaceutical preparations; solubilization chemicals for diagnostic research; chemical additives for use as binding agents in pharmaceuticals; chemical agents used for improving stability, bioavailability and dosing of pharmaceutical ingredients
CYDEX PHARMACEUTICALS	(3760106) 77681160	Cydex Pharmaceuticals, Inc. (DE)	1: Solubilizing chemical agents for use in the manufacture of pharmaceutical preparations
	(3713386) 77978066	Cydex Pharmaceuticals, Inc. (DE)	1: Solubilizing chemical agents for use in the manufacture of pharmaceutical preparations 45: licensing of excipient pharmaceutical products
CYDEX	(3479381) 77262367	Cydex Pharmaceuticals, Inc. (DE)	45: licensing of excipient pharmaceutical products

Mark	(Reg) / Serial No.	Owner	Goods / Services
ADVASEP	(2205608) 75369706	Cydex Pharmaceuticals, Inc. (DE)	1: Sulfobutylether substituted cyclodextrins for use in chemical analysis, primarily via capillary electrophoresis for scientific laboratory research use
CAPTISOL	(2086224) 74607013	Cydex Pharmaceuticals, Inc. (DE)	1: solubilization chemicals for diagnostic research
BONSITY	(6153490) 87289416	Pfenex Inc.	5: pharmaceutical preparations, namely, pharmaceuticals used for the prevention and treatment of bone and skeletal diseases

179584468